Tivic Health Systems Reports $2.6 Million Net Loss in Q3 2025, Revenue Increases 16%

Tivic Health Systems, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $2.6 million, compared to a loss of $1.4 million in the same period last year. For the nine months ended September 30, 2025, the company incurred a net loss of $6.0 million, significantly higher than the $4.2 million loss recorded in the prior year. Revenue for the third quarter increased to $146,000, a 16% rise from $126,000 in the same quarter of 2024, but total revenue for the nine months decreased by 50% to $302,000 from $600,000 year-over-year. The decline in nine-month revenue was attributed to a 45% drop in unit sales as the company shifted focus from its consumer health product, ClearUP, to its biopharmaceutical pipeline.

The company’s operating expenses surged to $2.3 million for the third quarter, up from $1.5 million in the prior year, driven by increased research and development costs associated with its new biopharmaceutical initiatives, particularly the TLR5 agonist, Entolimod. Research and development expenses rose to $858,000 in the third quarter, compared to $422,000 in the same period last year. General and administrative expenses also increased, reflecting higher costs related to investor relations and legal fees. The company’s accumulated deficit reached $49.6 million as of September 30, 2025.

In terms of strategic developments, Tivic Health has made significant moves in its biopharmaceutical operations, including acquiring an exclusive license for Entolimod from Statera Biopharma in February 2025. The company has since exercised its option to license additional indications for Entolimod, focusing on advancing its clinical studies. The company is winding down its consumer health business, which has been a significant source of revenue, and expects minimal revenue generation until it can commercialize its new product candidates.

Operationally, Tivic Health has seen a notable increase in its cash position, with cash and cash equivalents rising to $3.5 million as of September 30, 2025, up from $2.0 million at the end of 2024. The company has also engaged in several financing activities, including a series of tranche closings under a Preferred Purchase Agreement, which has provided approximately $4.9 million in gross proceeds. However, the company has indicated that it will require additional capital to fund ongoing operations and clinical trials, raising concerns about its ability to continue as a going concern within the next year.

Looking ahead, Tivic Health anticipates continued operating losses as it invests in the development of its product candidates. The company is focused on obtaining regulatory approval for Entolimod and plans to reduce costs associated with its consumer health business. The management has expressed uncertainty regarding future revenues, particularly as it winds down the ClearUP business, and is actively exploring additional funding options to support its operations and growth strategy.